Search

Your search keyword '"Boer, A. M."' showing total 17 results
Start Over Author "Boer, A. M." Journal leukemia
17 results on '"Boer, A. M."'

1. Integration of genetics and MRD to define low risk patients with B-cell precursor acute lymphoblastic leukaemia with intermediate MRD levels at the end of induction

Author

Moorman, Anthony V., Enshaei, Amir, Murdy, Daniel, Joy, Melvin, Boer, Judith M., den Boer, Monique L., Pieters, Rob, de Haas, Valerie, Horstmann, Martin A., Escherich, Gabriele, Johansson, Bertil, Marquart, Hanne V., Schmiegelow, Kjeld, Hancock, Jeremy, Moppett, John, and Heyman, Mats

Published
2024
Full Text
View/download PDF

2. Clinical characteristics and outcomes of B-cell precursor ALL with MEF2D rearrangements: a retrospective study by the Ponte di Legno Childhood ALL Working Group

Author

Ohki, Kentaro, Butler, Ellie R., Kiyokawa, Nobutaka, Hirabayashi, Shinsuke, Bergmann, Anke K., Möricke, Anja, Boer, Judith M., Cavé, Hélène, Cazzaniga, Giovanni, Yeoh, Allen Eng Juh, Sanada, Masashi, Imamura, Toshihiko, Inaba, Hiroto, Mullighan, Charles G., Loh, Mignon L., Norén-Nyström, Ulrika, Shih, Lee-Yung, Zaliova, Marketa, Pui, Ching-Hon, Haas, Oskar A., Harrison, Christine J., Moorman, Anthony V., and Manabe, Atsushi

Published
2023
Full Text
View/download PDF

3. Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial

Author

Pennesi, Edoardo, Michels, Naomi, Brivio, Erica, van der Velden, Vincent H. J., Jiang, Yilin, Thano, Adriana, Ammerlaan, Anneke J. C., Boer, Judith M., Beverloo, H. Berna, Sleight, Barbara, Chen, Ying, Vormoor-Bürger, Britta, Rives, Susana, Bielorai, Bella, Rössig, Claudia, Petit, Arnaud, Rizzari, Carmelo, Engstler, Gernot, Starý, Jan, Bautista Sirvent, Francisco J., Chen-Santel, Christiane, Bruno, Benedicte, Bertrand, Yves, Rialland, Fanny, Plat, Geneviève, Reinhardt, Dirk, Vinti, Luciana, Von Stackelberg, Arend, Locatelli, Franco, and Zwaan, Christian M.

Published
2022
Full Text
View/download PDF

4. Clinical characteristics and outcomes of B-ALL with ZNF384 rearrangements: a retrospective analysis by the Ponte di Legno Childhood ALL Working Group

Author

Hirabayashi, Shinsuke, Butler, Ellie R., Ohki, Kentaro, Kiyokawa, Nobutaka, Bergmann, Anke K., Möricke, Anja, Boer, Judith M., Cavé, Hélène, Cazzaniga, Giovanni, Yeoh, Allen Eng Juh, Sanada, Masashi, Imamura, Toshihiko, Inaba, Hiroto, Mullighan, Charles, Loh, Mignon L., Norén-Nyström, Ulrika, Pastorczak, Agata, Shih, Lee-Yung, Zaliova, Marketa, Pui, Ching-Hon, Haas, Oskar A., Harrison, Christine J., Moorman, Anthony V., and Manabe, Atsushi

Published
2021
Full Text
View/download PDF

5. Favorable outcome of NUTM1-rearranged infant and pediatric B cell precursor acute lymphoblastic leukemia in a collaborative international study

Author

Boer, Judith M., Valsecchi, Maria Grazia, Hormann, Femke M., Antić, Željko, Zaliova, Marketa, Schwab, Claire, Cazzaniga, Giovanni, Arfeuille, Chloé, Cavé, Hélène, Attarbaschi, Andishe, Strehl, Sabine, Escherich, Gabriele, Imamura, Toshihiko, Ohki, Kentaro, Grüber, Tanja A., Sutton, Rosemary, Pastorczak, Agata, Lammens, Tim, Lambert, Frédéric, Li, Chi Kong, Carrillo de Santa Pau, Enrique, Hoffmann, Steve, Möricke, Anja, Harrison, Christine J., Den Boer, Monique L., De Lorenzo, Paola, Stam, Ronald W., Bergmann, Anke K., and Pieters, Rob

Published
2021
Full Text
View/download PDF

6. Clinical characteristics and outcomes of B-cell precursor ALL with MEF2D rearrangements: a retrospective study by the Ponte di Legno Childhood ALL Working Group

Author

Ohki, Kentaro, primary, Butler, Ellie R., additional, Kiyokawa, Nobutaka, additional, Hirabayashi, Shinsuke, additional, Bergmann, Anke K., additional, Möricke, Anja, additional, Boer, Judith M., additional, Cavé, Hélène, additional, Cazzaniga, Giovanni, additional, Yeoh, Allen Eng Juh, additional, Sanada, Masashi, additional, Imamura, Toshihiko, additional, Inaba, Hiroto, additional, Mullighan, Charles G., additional, Loh, Mignon L., additional, Norén-Nyström, Ulrika, additional, Shih, Lee-Yung, additional, Zaliova, Marketa, additional, Pui, Ching-Hon, additional, Haas, Oskar A., additional, Harrison, Christine J., additional, Moorman, Anthony V., additional, and Manabe, Atsushi, additional

Published
2022
Full Text
View/download PDF

7. Prognostic value of rare IKZF1 deletion in childhood B-cell precursor acute lymphoblastic leukemia: an international collaborative study

Author

Boer, J M, van der Veer, A, Rizopoulos, D, Fiocco, M, Sonneveld, E, de Groot-Kruseman, H A, Kuiper, R P, Hoogerbrugge, P, Horstmann, M, Zaliova, M, Palmi, C, Trka, J, Fronkova, E, Emerenciano, M, do Socorro Pombo-de-Oliveira, M, Mlynarski, W, Szczepanski, T, Nebral, K, Attarbaschi, A, Venn, N, Sutton, R, Schwab, C J, Enshaei, A, Vora, A, Stanulla, M, Schrappe, M, Cazzaniga, G, Conter, V, Zimmermann, M, Moorman, A V, Pieters, R, and den Boer, M L

Published
2016
Full Text
View/download PDF

10. Clinical characteristics and outcomes of B-cell precursor ALL with MEF2Drearrangements: a retrospective study by the Ponte di Legno Childhood ALL Working Group

Author

Ohki, Kentaro, Butler, Ellie R., Kiyokawa, Nobutaka, Hirabayashi, Shinsuke, Bergmann, Anke K., Möricke, Anja, Boer, Judith M., Cavé, Hélène, Cazzaniga, Giovanni, Yeoh, Allen Eng Juh, Sanada, Masashi, Imamura, Toshihiko, Inaba, Hiroto, Mullighan, Charles G., Loh, Mignon L., Norén-Nyström, Ulrika, Shih, Lee-Yung, Zaliova, Marketa, Pui, Ching-Hon, Haas, Oskar A., Harrison, Christine J., Moorman, Anthony V., and Manabe, Atsushi

Published
2023
Full Text
View/download PDF

12. RAS pathway mutations as a predictive biomarker for treatment adaptation in pediatric B-cell precursor acute lymphoblastic leukemia

Author

Jerchel, I S, primary, Hoogkamer, A Q, additional, Ariës, I M, additional, Steeghs, E M P, additional, Boer, J M, additional, Besselink, N J M, additional, Boeree, A, additional, van de Ven, C, additional, de Groot-Kruseman, H A, additional, de Haas, V, additional, Horstmann, M A, additional, Escherich, G, additional, Zwaan, C M, additional, Cuppen, E, additional, Koudijs, M J, additional, Pieters, R, additional, and den Boer, M L, additional

Published
2017
Full Text
View/download PDF

13. Clinical characteristics and outcomes of B-ALL with ZNF384rearrangements: a retrospective analysis by the Ponte di Legno Childhood ALL Working Group

Author

Hirabayashi, Shinsuke, Butler, Ellie R., Ohki, Kentaro, Kiyokawa, Nobutaka, Bergmann, Anke K., Möricke, Anja, Boer, Judith M., Cavé, Hélène, Cazzaniga, Giovanni, Yeoh, Allen Eng Juh, Sanada, Masashi, Imamura, Toshihiko, Inaba, Hiroto, Mullighan, Charles, Loh, Mignon L., Norén-Nyström, Ulrika, Pastorczak, Agata, Shih, Lee-Yung, Zaliova, Marketa, Pui, Ching-Hon, Haas, Oskar A., Harrison, Christine J., Moorman, Anthony V., and Manabe, Atsushi

Published
2021
Full Text
View/download PDF

14. Prognostic value of rare IKZF1 deletion in childhood B-cell precursor acute lymphoblastic leukemia: an international collaborative study

Author

Boer, J M, primary, van der Veer, A, additional, Rizopoulos, D, additional, Fiocco, M, additional, Sonneveld, E, additional, de Groot-Kruseman, H A, additional, Kuiper, R P, additional, Hoogerbrugge, P, additional, Horstmann, M, additional, Zaliova, M, additional, Palmi, C, additional, Trka, J, additional, Fronkova, E, additional, Emerenciano, M, additional, do Socorro Pombo-de-Oliveira, M, additional, Mlynarski, W, additional, Szczepanski, T, additional, Nebral, K, additional, Attarbaschi, A, additional, Venn, N, additional, Sutton, R, additional, Schwab, C J, additional, Enshaei, A, additional, Vora, A, additional, Stanulla, M, additional, Schrappe, M, additional, Cazzaniga, G, additional, Conter, V, additional, Zimmermann, M, additional, Moorman, A V, additional, Pieters, R, additional, and den Boer, M L, additional

Published
2015
Full Text
View/download PDF

15. RAS pathway mutations as a predictive biomarker for treatment adaptation in pediatric B-cell precursor acute lymphoblastic leukemia

Author

Jerchel, I S, Hoogkamer, A Q, Ariës, I M, Steeghs, E M P, Boer, J M, Besselink, N J M, Boeree, A, van de Ven, C, de Groot-Kruseman, H A, de Haas, V, Horstmann, M A, Escherich, G, Zwaan, C M, Cuppen, E, Koudijs, M J, Pieters, R, and den Boer, M L

Abstract

RAS pathway mutations have been linked to relapse and chemotherapy resistance in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL). However, comprehensive data on the frequency and prognostic value of subclonal mutations in well-defined subgroups using highly sensitive and quantitative methods are lacking. Targeted deep sequencing of 13 RAS pathway genes was performed in 461 pediatric BCP-ALL cases at initial diagnosis and in 19 diagnosis-relapse pairs. Mutations were present in 44.2% of patients, with 24.1% carrying a clonal mutation. Mutation frequencies were highest in high hyperdiploid, infant t(4;11)-rearranged, BCR-ABL1-like and B-other cases (50–70%), whereas mutations were less frequent in ETV6-RUNX1-rearranged, and rare in TCF3-PBX1- and BCR-ABL1-rearranged cases (27–4%). RAS pathway-mutated cells were more resistant to prednisolone and vincristine ex vivo. Clonal, but not subclonal, mutations were linked to unfavorable outcome in standard- and high-risk-treated patients. At relapse, most RAS pathway mutations were clonal (9 of 10). RAS mutant cells were sensitive to the MEK inhibitor trametinib ex vivo, and trametinib sensitized resistant cells to prednisolone. We conclude that RAS pathway mutations are frequent, and that clonal, but not subclonal, mutations are associated with unfavorable risk parameters in newly diagnosed pediatric BCP-ALL. These mutations may designate patients eligible for MEK inhibitor treatment.

Published
2018
Full Text
View/download PDF

17. Prognostic value of rare IKZF1deletion in childhood B-cell precursor acute lymphoblastic leukemia: an international collaborative study

Author

Boer, J M, van der Veer, A, Rizopoulos, D, Fiocco, M, Sonneveld, E, de Groot-Kruseman, H A, Kuiper, R P, Hoogerbrugge, P, Horstmann, M, Zaliova, M, Palmi, C, Trka, J, Fronkova, E, Emerenciano, M, do Socorro Pombo-de-Oliveira, M, Mlynarski, W, Szczepanski, T, Nebral, K, Attarbaschi, A, Venn, N, Sutton, R, Schwab, C J, Enshaei, A, Vora, A, Stanulla, M, Schrappe, M, Cazzaniga, G, Conter, V, Zimmermann, M, Moorman, A V, Pieters, R, and den Boer, M L

Abstract

Deletions in IKZF1are found in ~15% of children with B-cell precursor acute lymphoblastic leukemia (BCP-ALL). There is strong evidence for the poor prognosis of IKZF1deletions affecting exons 4–7 and exons 1–8, but evidence for the remaining 33% of cases harboring other variants of IKZF1deletions is lacking. In an international multicenter study we analyzed the prognostic value of these rare variants in a case–control design. Each IKZF1-deleted case was matched to three IKZF1wild-type controls based on cytogenetic subtype, treatment protocol, risk stratification arm, white blood cell count and age. Hazard ratios for the prognostic impact of rare IKZF1deletions on event-free survival were calculated by matched pair Cox regression. Matched pair analysis for all 134 cases with rare IKZF1deletions together revealed a poor prognosis (P<0.001) that was evident in each risk stratification arm. Rare variant types with the most unfavorable event-free survival were DEL 2–7 (P=0.03), DEL 2–8 (P=0.002) and DEL-Other (P<0.001). The prognosis of each type of rare variant was equal or worse compared with the well-known major DEL 4–7 and DEL 1–8 IKZF1deletion variants. We therefore conclude that all variants of rare IKZF1deletions are associated with an unfavorable prognosis in pediatric BCP-ALL.

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results